EBV ZEBRA Transactivator PDF Print E-mail

A Monoclonal antibody that demonstrates significant potential as a research and/or diagnostic tool (virology, cancer research, immune-biology)


The ZEBRA transactivator is an Epstein-Barr Virus (EBV) protein transactivator controlling the switch of the viral cycle from a latent to productive phase. The Zebra transactivator acts by binding to the promoters of genes involved in lytic DNA replication and activating their transcription. This protein transactivator demonstrates significant potential within a research environment (virology, cancer research, immune-biology) as well as in diagnostics.


  • Monoclonal Antibody
    • Highly targeted
  • Validated for use in immunofluorescence/western blotting/Flow cytometry
    • Especially useful within a research environment
  • UVHCI (Unit of Virus Host Cell Interactions), laboratory renowned at a European level
    • Specialists in the understanding of EBV biology, the team is able to provide a high level of technical support.


This research/diagnostic tool shows significant potential in all of the following fields:

  • Virology
  • Cancer Research
  • Immune biology

Scientific Data

Name: EBV - ZEBRA transactivator
Description: Two hybridomas have been developed to target this protein: one against the p130 epitope, a ZEBRA DNA-binding domain, and a second targeting the p125 epitope.
Specific marker for the early detection of EBV infection
Clone AZ125 (IgG) // AZ130 (IgG)
Host species
Mouse monoclonal IgGs
Ig subclass The antibody is effective in immunoblotting, cytochemistry, immunohistochemistry
Culture medium RPMI 1640 with FCS GIBCO (Invitrogene) 10%










References :

Le Roux et al. J. Gen. Virol. 77 : 501-509, 1996
Segouffin et al. J. Gen. Virol. 77 : 1529-1536, 1997
Drouet E. et al. J. Med. Virol. 57 : 383-389, 1999
Imbert-Marcille et al. Clin. Diagn. Lab. Immunol. 7 : 206-211. 2000

Commercial Opportunities

This technology is available to license to organisations working in the field of monoclonal antibody distribution.


Technology Transfer Manager
Pascale Grenard-Ecuyer
+33 476 00 78 34
This e-mail address is being protected from spambots. You need JavaScript enabled to view it




“We are convinced of the usefulness of BGENE’s customized sequence modification service on bacterial genomes or vectors without scarring"  European biotech company